ANEW MEDICAL, INC.’s shares and warrants are expected to begin trading on the Nasdaq Global Market under the tickers “WENA” and “WENAW”, respectively. NEW YORK, NY, June 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or the “Company”), a biopharmaceutical technology company focused on developing disruptive new therapies to treat the central nervous system (“CNS”) and neurodegenerative diseases, and Redwoods Acquisition Corp. (NASDAQ: RWOD) (“RWOD”), a publicly-traded special purpose acq
Redwoods Acquisition Corp. (NASDAQ:RWOD) shares traded higher on Friday after the company announced that shareholders had approved its merger agreement with Anew Medical. Following the consummation of the transactions, Redwoods will change its name to Anew Medical, the company said in an exchange filing (April 18). On May 30, 2023, Redwoods Acquisition entered into a business combination agreement with Anew Medical Sub, Inc. The transaction values the combined company at a pro forma enterprise v
Key Insights Significant control over Redwoods Acquisition by retail investors implies that the general public has more...